Gilead Sciences, Inc. (NASDAQ:GILD) Stake Boosted by Human Investing LLC

Human Investing LLC raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.0% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 3,463 shares of the biopharmaceutical company’s stock after buying an additional 195 shares during the quarter. Human Investing LLC’s holdings in Gilead Sciences were worth $290,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. CarsonAllaria Wealth Management Ltd. lifted its holdings in Gilead Sciences by 198.3% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 238 shares during the period. nVerses Capital LLC acquired a new position in shares of Gilead Sciences in the 3rd quarter worth $25,000. Valued Wealth Advisors LLC raised its holdings in Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares during the period. Palisade Asset Management LLC purchased a new stake in shares of Gilead Sciences in the 1st quarter valued at approximately $29,000. Finally, Cedar Wealth Management LLC boosted its position in shares of Gilead Sciences by 51.6% in the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 160 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares in the company, valued at $6,545,480.06. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 36,847 shares of company stock worth $3,033,340 over the last ninety days. 0.16% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts recently commented on GILD shares. Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $74.00 to $96.00 in a research report on Monday, October 21st. Truist Financial increased their price objective on Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. Wells Fargo & Company raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $78.00 to $100.00 in a research report on Monday, October 7th. Evercore ISI raised shares of Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. Finally, JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $95.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, October 9th. Ten analysts have rated the stock with a hold rating, eleven have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.85.

Gilead Sciences Trading Up 0.1 %

NASDAQ GILD traded up $0.08 during trading hours on Friday, hitting $88.90. The company’s stock had a trading volume of 1,024,500 shares, compared to its average volume of 6,997,148. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $89.74. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. The firm has a market capitalization of $110.68 billion, a P/E ratio of 108.32, a PEG ratio of 3.07 and a beta of 0.18. The stock has a fifty day moving average of $83.54 and a 200 day moving average of $73.97.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The business had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. Equities research analysts forecast that Gilead Sciences, Inc. will post 3.76 earnings per share for the current fiscal year.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.